



## SOME DRUGS AND HERBAL PRODUCTS

VOLUME 108

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 4–11 June 2013

Lyon, France - 2016

IARC MONOGRAPHS  
ON THE EVALUATION  
OF CARCINOGENIC RISKS  
TO HUMANS

# CONTENTS

---

<b>NOTE TO THE READER.....</b>	<b>1</b>
<b>LIST OF PARTICIPANTS.....</b>	<b>3</b>
<b>PREAMBLE.....</b>	<b>7</b>
<b>A. GENERAL PRINCIPLES AND PROCEDURES .....</b>	<b>7</b>
1. Background.....	7
2. Objective and scope.....	8
3. Selection of agents for review .....	9
4. Data for the <i>Monographs</i> .....	9
5. Meeting participants .....	10
6. Working procedures.....	11
<b>B. SCIENTIFIC REVIEW AND EVALUATION .....</b>	<b>12</b>
1. Exposure data.....	13
2. Studies of cancer in humans.....	14
3. Studies of cancer in experimental animals.....	18
4. Mechanistic and other relevant data.....	21
5. Summary .....	24
6. Evaluation and rationale.....	25
References.....	29
<b>GENERAL REMARKS .....</b>	<b>31</b>
<b>ALOE VERA.....</b>	<b>37</b>
1. Exposure Data.....	37
1.1 Identification of the agent .....	37
1.2 Analysis .....	43
1.3 Use.....	46
1.4 Production, sales, and consumption.....	47
1.5 Occupational exposure .....	51
1.6 Regulations and guidelines .....	51

2. Cancer in Humans .....	51
3. Cancer in Experimental Animals .....	51
3.1 Studies of carcinogenicity .....	51
3.2 Photo-co-carcinogenicity studies .....	52
4. Mechanistic and Other Relevant Data .....	55
4.1 Absorption, distribution, metabolism, and excretion .....	55
4.2 Genetic and related effects .....	57
4.3 Toxic effects and other mechanistic data .....	63
4.4 Other mechanistic data .....	64
4.5 Susceptibility .....	64
4.6 Mechanistic considerations .....	64
5. Summary of Data Reported .....	65
5.1 Exposure data .....	65
5.2 Human carcinogenicity data .....	66
5.3 Animal carcinogenicity data .....	66
5.4 Mechanistic and other relevant data .....	66
6. Evaluation .....	66
6.1 Cancer in humans .....	66
6.2 Cancer in experimental animals .....	67
6.3 Overall evaluation .....	67
References .....	67
<b>GOLDENSEAL .....</b>	<b>73</b>
1. Exposure Data .....	73
1.1 Identification of the agent and its major constituents .....	73
1.2 Analysis .....	75
1.3 Use .....	75
1.4 Production, sales, and consumption .....	77
1.5 Occupational exposure .....	78
1.6 Regulations and guidelines .....	78
2. Cancer in Humans .....	78
3. Cancer in Experimental Animals .....	78
3.1 Mouse .....	78
3.2 Rat .....	78
4. Mechanistic and Other Relevant Data .....	80
4.1 Absorption, distribution, metabolism, and excretion .....	80
4.2 Genetic and related effects .....	82
4.3 Other mechanistic data relevant to carcinogenicity .....	84
4.4 Susceptibility .....	84
4.5 Mechanistic considerations .....	84
5. Summary of Data Reported .....	85
5.1 Exposure data .....	85
5.2 Human carcinogenicity data .....	85
5.3 Animal carcinogenicity data .....	85
5.4 Mechanistic and other relevant data .....	85

6. Evaluation.....	86
6.1 Cancer in humans.....	86
6.2 Cancer in experimental animals.....	86
6.3 Overall evaluation.....	86
References.....	86
<b>GINKGO BILOBA.....</b>	<b>91</b>
1. Exposure Data.....	91
1.1 Identification of the agent.....	91
1.2 Analysis.....	95
1.3 Uses.....	96
1.4 Production, sales, and consumption.....	96
1.5 Occupational exposure.....	97
1.6 Regulations and guidelines.....	97
2. Cancer in Humans.....	97
2.1 Background.....	97
2.2 Randomized controlled trial.....	98
2.3 Case-control studies.....	98
3. Cancer in Experimental Animals.....	102
3.1 Mouse.....	102
3.2 Rat.....	105
4. Mechanistic and Other Relevant Data.....	105
4.1 Absorption, distribution, metabolism, and excretion.....	105
4.2 Genetic and related effects.....	108
4.3 Other mechanistic data relevant to carcinogenicity.....	109
4.4 Susceptibility.....	110
4.5 Mechanistic considerations.....	110
5. Summary of Data Reported.....	110
5.1 Exposure data.....	110
5.2 Human carcinogenicity data.....	110
5.3 Animal carcinogenicity data.....	111
5.4 Mechanistic and other relevant data.....	111
6. Evaluation.....	111
6.1 Cancer in humans.....	111
6.2 Cancer in experimental animals.....	111
6.3 Overall evaluation.....	111
References.....	112
<b>KAVA.....</b>	<b>117</b>
1. Exposure Data.....	117
1.1 Identification of the agent.....	117
1.2 Analysis.....	120
1.3 Use.....	120
1.4 Production, sales, and consumption.....	123
1.5 Occupational exposure.....	125
1.6 Regulations and guidelines.....	125

2. Cancer in Humans	125
3. Cancer in Experimental Animals	126
3.1 Mouse	126
3.2 Rat	126
4. Mechanistic and Other Relevant Data	128
4.1 Absorption, distribution, metabolism, and excretion	128
4.2 Genetic and related effects	130
4.3 Other mechanistic data relevant to carcinogenesis	135
4.4 Susceptibility	135
4.5 Mechanistic considerations	136
5. Summary of Data Reported	136
5.1 Exposure data	136
5.2 Human carcinogenicity data	136
5.3 Animal carcinogenicity data	136
5.4 Mechanistic and other relevant data	136
6. Evaluation	137
6.1 Cancer in humans	137
6.2 Cancer in experimental animals	137
6.3 Overall evaluation	137
References	137
<b>PULEGONE</b>	<b>141</b>
1. Exposure Data	141
1.1 Identification of the agent	141
1.2 Production and use	142
1.3 Occurrence and exposure	142
1.4 Regulations and guidelines	143
2. Cancer in Humans	143
3. Cancer in Experimental Animals	143
3.1 Mouse	143
3.2 Rat	145
4. Mechanistic and Other Relevant Data	145
4.1 Absorption, distribution, metabolism, and excretion	145
4.2 Genetic and related effects	149
4.3 Other mechanistic data	149
4.4 Susceptibility	151
4.5 Mechanistic considerations	151
5. Summary of Data Reported	151
5.1 Exposure data	151
5.2 Human carcinogenicity data	152
5.3 Animal carcinogenicity data	152
5.4 Mechanistic and other relevant data	152
6. Evaluation	152
6.1 Cancer in humans	152
6.2 Cancer in experimental animals	152
6.3 Overall evaluation	152
References	152

---

<b>METHYLENE BLUE</b> .....	<b>155</b>
1. Exposure Data .....	155
1.1 Chemical and physical data .....	155
1.2 Analysis .....	156
1.3 Production and use .....	156
1.4 Occurrence and exposure .....	162
1.5 Regulations and guidelines .....	162
2. Cancer in Humans .....	164
3. Cancer in Experimental Animals .....	164
3.1 Mouse .....	164
3.2 Rat .....	164
4. Mechanistic and Other Relevant Data .....	165
4.1 Absorption, distribution, metabolism, and excretion .....	165
4.2 Genetic and related effects .....	168
4.3 Other relevant mechanisms .....	176
4.4 Susceptibility .....	177
4.5 Mechanistic considerations .....	177
5. Summary of Data Reported .....	178
5.1 Exposure data .....	178
5.2 Human carcinogenicity data .....	178
5.3 Animal carcinogenicity data .....	178
5.4 Mechanistic and other relevant data .....	178
6. Evaluation .....	179
6.1 Cancer in humans .....	179
6.2 Cancer in experimental animals .....	179
6.3 Overall evaluation .....	179
References .....	179
<b>PRIMIDONE</b> .....	<b>185</b>
1. Exposure Data .....	185
1.1 Identification of the agent .....	185
1.2 Analysis .....	186
1.3 Production and use .....	186
1.4 Occurrence and exposure .....	189
1.5 Regulations and guidelines .....	190
2. Cancer in Humans .....	190
2.1 Cohort studies .....	190
2.2 Nested case-control studies .....	191
3. Cancer in Experimental Animals .....	193
3.1 Mouse .....	193
3.2 Rat .....	194
4. Mechanistic and Other Relevant Data .....	194
4.1 Absorption, distribution, metabolism, and excretion .....	194
4.2 Genetic and related effects .....	199
4.3 Other mechanistic data relevant to carcinogenesis .....	201
4.4 Susceptibility .....	202
4.5 Mechanistic considerations .....	202

5. Summary of Data Reported .....	203
5.1 Exposure data .....	203
5.2 Human carcinogenicity data .....	203
5.3 Animal carcinogenicity data .....	203
5.4 Mechanistic and other relevant data .....	203
6. Evaluation .....	204
6.1 Cancer in humans .....	204
6.2 Cancer in experimental animals .....	204
6.3 Overall evaluation .....	204
References .....	204

<b>SULFASALAZINE .....</b>	<b>209</b>
1. Exposure Data .....	209
1.1 Identification of the agent .....	209
1.2 Production .....	210
1.3 Occurrence and exposure .....	214
1.4 Regulations and guidelines .....	215
2. Cancer in Humans .....	215
2.1 Background .....	215
2.2 Longitudinal, cohort, and nested case–control studies .....	215
2.3 Case–control studies .....	221
2.4 Meta-analysis .....	222
3. Cancer in Experimental Animals .....	222
3.1 Mouse .....	222
3.2 Rat .....	224
3.3 Studies of co-carcinogenicity .....	226
4. Mechanistic and Other Relevant Data .....	226
4.1 Absorption, distribution, metabolism, and excretion .....	226
4.2 Genetic and related effects .....	233
4.3 Other mechanistic data relevant to carcinogenicity .....	239
4.4 Susceptibility .....	241
4.5 Mechanistic considerations .....	241
5. Summary of Data Reported .....	242
5.1 Exposure data .....	242
5.2 Human carcinogenicity data .....	242
5.3 Animal carcinogenicity data .....	243
5.4 Mechanistic and other relevant data .....	243
6. Evaluation .....	244
6.1 Cancer in humans .....	244
6.2 Cancer in experimental animals .....	244
6.3 Overall evaluation .....	244
References .....	244

---

<b>PENTOSAN POLYSULFATE SODIUM.....</b>	<b>251</b>
1. Exposure Data .....	251
1.1 Chemical and physical data.....	251
1.2 Analysis .....	252
1.3 Production.....	252
1.4 Occurrence and exposure.....	255
1.5 Regulations and guidelines .....	255
2. Cancer in Humans .....	255
3. Cancer in Experimental Animals .....	255
3.1 Mouse.....	255
3.2 Rat .....	256
4. Mechanistic and Other Relevant Data .....	257
4.1 Absorption, distribution, metabolism, and excretion .....	257
4.2 Genetic and related effects .....	258
4.3 Other mechanistic data relevant to carcinogenicity .....	259
4.4 Susceptibility .....	260
4.5 Mechanistic considerations.....	260
5. Summary of Data Reported .....	260
5.1 Exposure data.....	260
5.2 Human carcinogenicity data.....	260
5.3 Animal carcinogenicity data.....	260
5.4 Mechanistic and other relevant data.....	260
6. Evaluation.....	261
6.1 Cancer in humans .....	261
6.2 Cancer in experimental animals.....	261
6.3 Overall evaluation .....	261
References.....	261
<b>TRIAMTERENE.....</b>	<b>263</b>
1. Exposure Data .....	263
1.1 Chemical and physical data.....	263
1.2 Analysis .....	264
1.3 Production and use.....	264
1.4 Occurrence and exposure.....	268
1.5 Regulations and guidelines .....	268
2. Cancer in Humans .....	268
2.1 Background.....	268
2.2 Triamterene and cancer of the breast .....	271
2.3 Combined use of triamterene and hydrochlorothiazide, and cancer of the lip .....	271
2.4 The drug class including triamterene, and cancer of the breast or colorectum .....	271
3. Cancer in Experimental Animals .....	272
3.1 Mouse.....	272
3.2 Rat .....	274



4. Mechanistic and Other Relevant Data .....	274
4.1 Absorption, distribution, metabolism, and excretion .....	274
4.2 Genetic and related effects .....	277
4.3 Other mechanistic data relevant to carcinogenicity .....	277
4.4 Susceptibility .....	278
4.5 Mechanistic considerations .....	279
5. Summary of Data Reported .....	279
5.1 Exposure data .....	279
5.2 Human carcinogenicity data .....	279
5.3 Animal carcinogenicity data .....	280
5.4 Mechanistic and other relevant data .....	280
6. Evaluation .....	280
6.1 Cancer in humans .....	280
6.2 Cancer in experimental animals .....	280
6.3 Overall evaluation .....	280
References .....	281

<b>HYDROCHLOROTHIAZIDE .....</b>	<b>285</b>
1. Exposure Data .....	285
1.1 Identification of the agent .....	285
1.2 Analysis .....	286
1.3 Production and use .....	286
1.4 Occurrence and exposure .....	290
1.5 Regulations and guidelines .....	290
2. Cancer in Humans .....	290
2.1 Cancers of the lip and skin .....	291
2.2 Renal cell carcinoma .....	301
2.3 Other cancers .....	302
3. Cancer in Experimental Animals .....	304
3.1 Oral administration .....	304
3.2 Coexposure with modifying agents .....	306
4. Mechanistic and Other Relevant Data .....	306
4.1 Absorption, distribution, metabolism, and excretion .....	306
4.2 Genetic and related effects .....	310
4.3 Other mechanistic data relevant to carcinogenicity .....	312
4.4 Susceptibility .....	312
4.5 Mechanistic considerations .....	312
5. Summary of Data Reported .....	312
5.1 Exposure data .....	312
5.2 Human carcinogenicity data .....	312
5.3 Animal carcinogenicity data .....	313
5.4 Mechanistic and other relevant data .....	314
6. Evaluation .....	314
6.1 Cancer in humans .....	314
6.2 Cancer in experimental animals .....	314
6.3 Overall evaluation .....	314
References .....	314

---

<b>PIOGLITAZONE AND ROSIGLITAZONE</b> .....	<b>319</b>
1. Exposure Data .....	319
1.1 Chemical and physical data on pioglitazone .....	319
1.2 Analysis of pioglitazone .....	321
1.3 Production and use of pioglitazone .....	321
1.4 Occurrence and exposure to pioglitazone .....	326
1.5 Regulations and guidelines for pioglitazone .....	326
1.6 Chemical and physical data on rosiglitazone .....	327
1.7 Analysis of rosiglitazone .....	328
1.8 Production and use of rosiglitazone .....	328
1.9 Occurrence and exposure to rosiglitazone .....	329
1.10 Regulations and guidelines for rosiglitazone .....	330
2. Cancer in Humans .....	331
2.1 Cancer of the bladder .....	339
2.2 Cancer of the liver .....	351
2.3 Cancer of the colorectum .....	351
2.4 Cancer of the lung .....	352
2.5 Cancer of the prostate .....	353
2.6 Cancer of the breast .....	353
2.7 Other site-specific cancers .....	353
3. Cancer in Experimental Animals .....	354
3.1 Pioglitazone .....	354
3.2 Rosiglitazone .....	357
4. Mechanistic and Other Relevant Data .....	361
4.1 Absorption, distribution, metabolism, and excretion of pioglitazone .....	361
4.2 Absorption, distribution, metabolism, and excretion of rosiglitazone .....	362
4.3 Genetic and related effects .....	364
4.4 Other mechanistic data .....	366
4.5 Susceptibility .....	369
4.6 Mechanistic considerations .....	369
5. Summary of Data Reported .....	371
5.1 Exposure data .....	371
5.2 Human carcinogenicity data .....	371
5.3 Animal carcinogenicity data .....	372
5.4 Mechanistic and other relevant data .....	373
6. Evaluation .....	373
6.1 Cancer in humans .....	373
6.2 Cancer in experimental animals .....	373
6.3 Overall evaluation .....	373
References .....	373

<b>DIGOXIN</b> .....	<b>381</b>
1. Exposure Data.....	381
1.1 Chemical and physical data.....	381
1.2 Analysis.....	383
1.3 Production and use.....	383
1.4 Occurrence and exposure.....	390
1.5 Regulations and guidelines.....	390
2. Cancer in Humans.....	390
2.1 Cancer of the breast.....	391
2.2 Cancers of the uterus and ovary.....	396
2.3 Cancer of the prostate.....	399
2.4 Non-Hodgkin lymphoma.....	399
2.5 Other cancer sites.....	403
3. Cancer in Experimental Animals.....	403
4. Mechanistic and Other Relevant Data.....	403
4.1 Absorption, distribution, metabolism, and excretion.....	403
4.2 Genetic and related effects.....	410
4.3 Other mechanistic data relevant to carcinogenicity.....	410
4.4 Susceptibility.....	411
4.5 Mechanistic considerations.....	412
5. Summary of Data Reported.....	412
5.1 Exposure data.....	412
5.2 Human carcinogenicity data.....	412
5.3 Animal carcinogenicity data.....	413
5.4 Mechanistic and other relevant data.....	413
6. Evaluation.....	414
6.1 Cancer in humans.....	414
6.2 Cancer in experimental animals.....	414
6.3 Overall evaluation.....	414
References.....	414
<b>LIST OF ABBREVIATIONS</b> .....	<b>421</b>

## NOTE TO THE READER

---

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

